65 results match your criteria: "United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City[Affiliation]"

Genetic mutations that yield defective cystic fibrosis transmembrane regulator () protein cause cystic fibrosis, a life-limiting autosomal recessive Mendelian disorder. A protective role of loss-of-function mutations in inflammatory bowel disease (IBD) has been suggested, but its evidence has been inconclusive and contradictory. Here, leveraging the largest IBD exome sequencing dataset to date, comprising 38,558 cases and 66,945 controls in the discovery stage, and 35,797 cases and 179,942 controls in the replication stage, we established a protective role of CF-risk variants against IBD based on evidence from the association test of delF508 (p-value=8.

View Article and Find Full Text PDF

Antiphospholipid syndrome (APS) diagnosis is dependent on the accurate detection and interpretation of antiphospholipid antibodies (aPL). Lupus anticoagulant (LA), anticardiolipin antibodies (aCL), and anti-beta2 glycoprotein I antibodies (aβ2GPI) remain the cornerstone of the laboratory part of APS diagnosis. In the 2023 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) APS classification criteria, the type of laboratory parameters remain essentially unchanged compared with the updated Sapporo classification criteria, and aCL and aβ2GPI measurement are still restricted to enzyme-linked immunosorbent assays (ELISAs) with moderate and high titer aPL thresholds defined as 40 and 80 Units, respectively, and a cutoff calculated by the 99th percentile has been abandoned.

View Article and Find Full Text PDF

EPAS1 Attenuates Atherosclerosis Initiation at Disturbed Flow Sites Through Endothelial Fatty Acid Uptake.

Circ Res

September 2024

Centre for Biochemical Pharmacology (S.T., B.T.-A., P.C.E.), William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom.

Background: Atherosclerotic plaques form unevenly due to disturbed blood flow, causing localized endothelial cell (EC) dysfunction. Obesity exacerbates this process, but the underlying molecular mechanisms are unclear. The transcription factor EPAS1 (HIF2A) has regulatory roles in endothelium, but its involvement in atherosclerosis remains unexplored.

View Article and Find Full Text PDF

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.

N Engl J Med

April 2024

From the Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City (M.N.K.); the School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (M.C.P.), the Diabetes Research Centre, University of Leicester, and the NIHR Leicester Biomedical Research Centre, Leicester (M.J.D.), and the Division of Cardiovascular Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester (F.Z.A.) - all in the United Kingdom; the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.); the Baylor Scott and White Research Institute, Dallas (J.B.); the Department of Medicine, University of Mississippi, Jackson (J.B.); Novo Nordisk, Søborg (G.K.H., D.V.M., M.B.T., T.J.J., K.L., M.L.L.), and the Department of Cardiology, Herlev-Gentofte Hospital, University of Copenhagen, Herlev (M. Schou) - both in Denmark; the Department of Cardiovascular Medicine and Section on Geriatrics and Gerontology, Wake Forest School of Medicine, Winston-Salem, NC (D.W.K.); the Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Unity Health Toronto, University of Toronto, Toronto (S.V.), and the University of Alberta, Edmonton (J.A.E.) - both in Canada; the College of Health and Medicine, Australian National University, Canberra, ACT, Australia (W.A.); the Heart Failure Unit, Cardiology Department, Rabin Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (T.B.-G.); Max Super Speciality Hospital, Saket, New Delhi, India (V.C.); the Section of Cardiology, Department of Medicine, Sahlgrenska University Hospital-Östra, Gothenburg, Sweden (M.F.); the Department of General Internal Medicine 3, Kawasaki Medical School, Okayama, Japan (H.I.); the Department of Noninvasive Cardiology, Medical University of Lodz, Lodz, Poland (M.L.); the Institute for Clinical and Experimental Medicine, Prague, Czech Republic (V.M.); the Heart and Vascular Center, Semmelweis University, Budapest, Hungary (B.M.); Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, and CIBER (Centro de Investigación Biomédica en Red) Cardiovascular - both in Valencia, Spain (J.N.); Instituto de Cardiologia J.F. Cabral, Corrientes, Argentina (E.P.); ASST (Azienda Socio Sanitaria Territoriale) Papa Giovanni XXIII, Bergamo, Italy (M. Senni); the Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore (K.S.); the Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (P.M.); the Medical University of Graz, Graz, Austria (D.V.L.); Cardiology and Angiology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany (D.W.); and the Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago (S.J.S.).

Article Synopsis
  • Obesity and type 2 diabetes are common in patients with heart failure with preserved ejection fraction, leading to significant symptoms, and there's a lack of approved treatments targeting this condition.
  • A study assigned 616 patients with heart failure, obesity, and type 2 diabetes to receive either once-weekly semaglutide or a placebo for one year, measuring improvements in symptoms and weight.
  • Results showed that those on semaglutide had significantly better improvements in symptom scores (KCCQ-CSS) and lost more body weight compared to the placebo group, along with other beneficial outcomes in physical activity and inflammation markers.
View Article and Find Full Text PDF

Background: The effects of lipid-lowering drug targets on different ischemic stroke subtypes are not fully understood. We aimed to explore the mechanisms by which lipid-lowering drug targets differentially affect the risk of ischemic stroke subtypes and their underlying pathophysiology.

Methods: Using a 2-sample Mendelian randomization approach, we assessed the effects of genetically proxied low-density lipoprotein cholesterol (LDL-c) and 3 clinically approved LDL-lowering drugs (HMGCR [3-hydroxy-3-methylglutaryl-CoA reductase], PCSK9 [proprotein convertase subtilisin/kexin type 9], and NPC1L1 [Niemann-Pick C1-Like 1]) on stroke subtypes and brain imaging biomarkers associated with small vessel stroke (SVS), including white matter hyperintensity volume and perivascular spaces.

View Article and Find Full Text PDF

Background: NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels are variably elevated in heart failure with preserved ejection fraction (HFpEF), even in the presence of increased left ventricular filling pressures. NT-proBNP levels are prognostic in HFpEF and have been used as an inclusion criterion for several recent randomized clinical trials. However, the underlying biologic differences between HFpEF participants with high and low NT-proBNP levels remain to be fully understood.

View Article and Find Full Text PDF

Spinocerebellar ataxia 27B: episodic symptoms and acetazolamide response in 34 patients.

Brain Commun

September 2023

Department of Neurology and Neurosurgery, Montreal Neurological Hospital and Institute, McGill University, Montreal, QC H3A 2B4, Canada.

Article Synopsis
  • - A study involving 34 patients from Canada, France, Austria, and Australia focused on spinocerebellar ataxia 27B, highlighting the shared symptom of episodic ataxia among these individuals.
  • - The report details various episodic features experienced by the patients, indicating that the condition is not just limited to ataxia but includes other episodic symptoms as well.
  • - It was found that acetazolamide, a medication often used for ataxia, proved ineffective in treating these patients, suggesting a need for alternative therapies.
View Article and Find Full Text PDF

Frequency of GAA- Ataxia in a Large Cohort of Brazilian Patients With Unsolved Adult-Onset Cerebellar Ataxia.

Neurol Genet

October 2023

From the Pós-graduação Em Medicina Interna e Ciências da Saúde (L.E.N., H.A.T.), Hospital de Clínicas da Universidade Federal do Paraná, Curitiba, Brazil; Department of Neuromuscular Diseases (L.E.N., D.P., S.A., P.I., A.C., H.H.), UCL Queen Square Institute of Neurology and the National Hospital for Neurology and Neurosurgery, London, UK; Department of Neurology (R.S.F., P.J.T., W.M.), School of Medicine at Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil; Departments of Neurology and Neurosurgery (D.P., M.-J.D., B.B.), Montreal Neurological Hospital and Institute, McGill University, Canada; Departamento de Neurologia (M.V.D.C.), Universidade do Estado do Amazonas, Manaus; Departamento de Especialidades Médicas (M.S.), Serviço de Neurologia, Universidade Estadual do Rio de Janeiro, Brazil; Department of Neurology (P.I.), Donostia University Hospital; Neuroscience Area (P.I.), Biodonostia Health Research Institute, San Sebastian; Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED) (P.I.), Spain; Department of Neurology (J.L.P., O.B.), Ataxia Unit, Universidade Federal de São Paulo, SP, Brazil; Department of Brain and Behavioral Sciences (A.C.), University of Pavia, Italy; Dr. John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics (M.C.D., S.Z.), University of Miami Miller School of Medicine; Department of Neurology (M.C.F.), School of Medical Sciences-University of Campinas (UNICAMP), São Paulo, Brazil; Department of Human Genetics (B.B.), McGill University, Montreal, Canada; and Laboratório Genetika (S.R.), Curitiba, PR, Brazil.

Objectives: Intronic GAA repeat expansions have recently been found to be a common cause of hereditary ataxia (GAA- ataxia; SCA27B). The global epidemiology and regional prevalence of this newly reported disorder remain to be established. In this study, we investigated the frequency of GAA- ataxia in a large cohort of Brazilian patients with unsolved adult-onset ataxia.

View Article and Find Full Text PDF

Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy.

N Engl J Med

May 2023

From the Section of Allergy and Immunology, Department of Pediatrics, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora (M.G., D.M.F.); the Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Stanford (S.B.S.), the University of California, San Francisco, San Francisco (M.J.D.), the David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (M.G.-L.), the University of California, San Diego, La Jolla (S.L.), and Rady Children's Hospital San Diego, San Diego (S.L.) - all in California; the Department of Pediatrics, Division of Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York (J.W., H.A.S.); the Department of Immunology, Perth Children's Hospital, and Telethon Kids Institute, Nedlands, WA (M.O.), Westmead Children's Hospital, Westmead, NSW (L.S.F., D.E.C.), Queensland Children's Hospital, University of Queensland, South Brisbane (J.P.), Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, VIC (K.P.P.), Women's and Children's Hospital, North Adelaide, SA (P.Q.), and Sydney Children's Hospital, Randwick, NSW (B.W.) - all in Australia; Guy's and St. Thomas' NHS Foundation Trust (G.T.), and the National Heart and Lung Institute, Imperial College London (P.J.T.), London, the Lydia Becker Institute of Immunology and Inflammation, University of Manchester and Royal Manchester Children's Hospital, Manchester (P.D.A.), University Hospital Southampton NHS Foundation Trust, Southampton (M.E.-L.), and Sheffield Children's NHS Foundation Trust, Sheffield (N.J.) - all in the United Kingdom; the Division of Pediatric Allergy and Immunology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill (E.H.K., A.W.B.); UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh (D.A., T.D.G.); Baylor College of Medicine, Houston (S.A.), UT Southwestern Medical Center and Children's Medical Center, Dallas (C.P.), and Dell Medical School at the University of Texas, Dell Children's Medical Center of Central Texas, Austin (P.V.) - all in Texas; Erasmus MC Sophia Children's Hospital, Rotterdam, the Netherlands (N.A.); Centre Hospitalier Universitaire (CHU) Sainte-Justine, Montreal (P.B.), British Columbia Children's Hospital, University of British Columbia, Vancouver (E.S.C.), the Translational Medicine Program, Research Institute, and the Department of Immunology (T.E.), and the Division of Immunology and Allergy, Department of Paediatrics (J.E.M.U.), Hospital for Sick Children, University of Toronto, Toronto - all in Canada; the Department of Children and Adolescent Medicine, Division of Pneumology, Allergology and Cystic Fibrosis, University Hospital Frankfurt, Goethe University, Frankfurt (K.B.), Philipps-Universität Marburg, Marburg (W.P.), and Universitätsklinikum Carl Gustav Carus, Dresden (C.V.) - all in Germany; Hôpitaux Pédiatriques de Nice CHU Lenval, Nice (T. Bourrier, L.G.-C.), Université de Lille, CHU Lille, Pediatric Pulmonology and Allergy Unit, Hôpital Jeanne de Flandre, Lille (A.D.), the Pediatric Allergy Unit, Children's Hospital, University Hospital of Nancy, and EA3450 Development, Adaptation and Handicap, Faculty of Medicine, University of Lorraine, Nancy (A.D.-C.), the Department of Pediatric Pulmonology and Allergy, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades, and University of Paris Cité, Paris (G.L.), and DBV Technologies, Montrouge (K.J.B., D.E.C., T.D.G., R.R., A.P., H.T.B., T. Bois, H.A.S.) - all in France; Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia (T.B.-W.); University of Arizona Medical Center, Tucson (H.C.); University of Chicago (C.E.C.), Northwestern University Feinberg School of Medicine (M.M.), and Ann and Robert H. Lurie Children's Hospital of Chicago (M.M., J.A.P., R.G.R.) - all in Chicago; the University of Tennessee Health Science Center, Memphis (J.A.L.); Vanderbilt University Medical Center, Nashville (S.L.D., R.G.R.); Karl Landsteiner University of Health Sciences, Krems, and the Department of Pediatric and Adolescent Medicine, University Hospital St. Pölten, St. Pölten - both in Austria (T.E.); Paediatrics and Child Health and the INFANT Center (J.O.H.) and the HRB Clinical Research Facility and the INFANT Research Center (J.T.), University College Cork, Cork University Hospital, Cork, and Paediatrics and Child Health, Royal College of Surgeons in Ireland, Dublin (J.O.H.) - both in Ireland; University of Arkansas for Medical Sciences and Arkansas Children's Hospital - both in Little Rock (S.M.J.); Cleveland Clinic, Cleveland (L.A.K.); the Division of Pulmonary, Allergy, and Sleep Medicine, Department of Pediatrics, Indiana University School of Medicine, Indianapolis (K.M.K.); University of Rochester, Rochester, NY (J.L., K.T.); Seattle Allergy and Asthma Research Institute, Seattle (D.P.); University of Michigan, Ann Arbor (G.S.); Boston Children's Hospital, Boston (L.S.); Children's National Health System, Washington, DC (H.P.S.); Emory University, Atlanta (B.P.V.); and Johns Hopkins Hospital, Baltimore (R.A.W.).

Background: No approved treatment for peanut allergy exists for children younger than 4 years of age, and the efficacy and safety of epicutaneous immunotherapy with a peanut patch in toddlers with peanut allergy are unknown.

Methods: We conducted this phase 3, multicenter, double-blind, randomized, placebo-controlled trial involving children 1 to 3 years of age with peanut allergy confirmed by a double-blind, placebo-controlled food challenge. Patients who had an eliciting dose (the dose necessary to elicit an allergic reaction) of 300 mg or less of peanut protein were assigned in a 2:1 ratio to receive epicutaneous immunotherapy delivered by means of a peanut patch (intervention group) or to receive placebo administered daily for 12 months.

View Article and Find Full Text PDF

Recessive diseases arise when both the maternal and the paternal copies of a gene are impacted by a damaging genetic variant in the affected individual. When a patient carries two different potentially causal variants in a gene for a given disorder, accurate diagnosis requires determining that these two variants occur on different copies of the chromosome (i.e.

View Article and Find Full Text PDF

The research of rare and devastating orphan diseases, such as idiopathic pulmonary fibrosis (IPF) has been limited by the rarity of the disease itself. The prognosis is poor-the prevalence of IPF is only approximately four times the incidence, limiting the recruitment of patients to trials and studies of the underlying biology. Global biobanking efforts can dramatically alter the future of IPF research.

View Article and Find Full Text PDF

Biobanks facilitate genome-wide association studies (GWASs), which have mapped genomic loci across a range of human diseases and traits. However, most biobanks are primarily composed of individuals of European ancestry. We introduce the Global Biobank Meta-analysis Initiative (GBMI)-a collaborative network of 23 biobanks from 4 continents representing more than 2.

View Article and Find Full Text PDF

Genome-wide association studies (GWAS) of human complex traits or diseases often implicate genetic loci that span hundreds or thousands of genetic variants, many of which have similar statistical significance. While statistical fine-mapping in individuals of European ancestries has made important discoveries, cross-population fine-mapping has the potential to improve power and resolution by capitalizing on the genomic diversity across ancestries. Here we present SuSiEx, an accurate and computationally efficient method for cross-population fine-mapping, which builds on the single-population fine-mapping framework, Sum of Single Effects (SuSiE).

View Article and Find Full Text PDF

FinnGen provides genetic insights from a well-phenotyped isolated population.

Nature

January 2023

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Article Synopsis
  • Population isolates like Finland provide a unique advantage for genetic research by having concentrated deleterious alleles in low-frequency variants due to historical bottlenecks.
  • The FinnGen study aims to analyze data from 500,000 Finnish individuals, focusing on their genomes and health records, particularly as many participants are older and have disease-related data.
  • From the analysis of 224,737 participants and additional biobank data, researchers discovered 30 new associations and a total of 2,733 significant genetic links across various diseases, highlighting the importance of low-frequency variants in understanding common diseases.
View Article and Find Full Text PDF

Meta-analysis is pervasively used to combine multiple genome-wide association studies (GWASs). Fine-mapping of meta-analysis studies is typically performed as in a single-cohort study. Here, we first demonstrate that heterogeneity (e.

View Article and Find Full Text PDF

Deep Intronic GAA Repeat Expansion in Late-Onset Cerebellar Ataxia.

N Engl J Med

January 2023

From the Departments of Neurology and Neurosurgery (D.P., M.-J.D., J.A.S., R.L., R. Sakalla, R.R., X.A.-C., R.M., C.H.C., A.-L.L., R.L.P., B.B.) and Pathology (J.A.S.), Montreal Neurological Hospital and Institute, McGill Genome Centre, Department of Human Genetics (S.J.R., J.R.), and the Departments of Diagnostic Radiology (R.L.P.) and Human Genetics (K.C., R.R., X.A.-C., B.B.), McGill University, Montreal Heart Institute (S.P., M.-P.D.), the Departments of Neurosciences (M.T., A.D.) and Medicine (M.P.D.), Faculty of Medicine, Université de Montréal, Université de Montréal Beaulieu-Saucier Pharmacogenomics Center (S.P.), Centre de Recherche du Centre Hospitalier de l'Université de Montréal (M.T., A.D.), and Centre de Réadaptation Lucie-Bruneau (A.D., B.B.), Montreal, the Faculty of Medicine and Health Sciences, Sherbrooke University, Sherbrooke, QC (J.M., F.E., M.-F.R.), and Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa (K.M.B.) - all in Canada; the Department of Neuromuscular Disease, UCL Queen Square Institute of Neurology and the National Hospital for Neurology and Neurosurgery (D.P., C.R., S.N., H.H.), the Department of Clinical and Movement Neurosciences and Queen Square Brain Bank for Neurological Disorders (Z.J.) and the Department of Neurodegenerative Disease (Z.C.), UCL Queen Square Institute of Neurology, University College London, and the Division of Neuropathology, National Hospital for Neurology and Neurosurgery, University College London NHS Foundation Trust (Z.J.) - all in London; Dr. John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics (M.C.D., S.F., C.Y., D.B., A.R., S.Z.), and the Department of Neurology (C.Y., M.A.S.), University of Miami Miller School of Medicine, Miami; the Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, and the German Center for Neurodegenerative Diseases - both in Tübingen, Germany (C.W., R. Schüle, L.S., M.S.); Service de Génétique Clinique et de Neurologie, Hôpital Brabois Enfants, and INSERM Unité 1256 N-GERE (Nutrition-Genetics and Environmental Risk Exposure), Université de Lorraine - both in Nancy, France (M.R.); Centre for Medical Research, University of Western Australia and Harry Perkins Institute of Medical Research (C.K.S., G.R., N.G.L.), the Department of Diagnostic Genomics, PathWest Laboratory Medicine, West Australian Department of Health (C.K.S.), and the Department of Neurology, Royal Perth Hospital (C.A., P.J.L.) - all in Perth, WA, Australia; the Ataxia and Hereditary Spastic Paraplegia Unit, Service of Neurology, Hospital Universitari de Girona Dr. Josep Trueta and Hospital Santa Caterina IAS, Girona (D.G.), and the Alzheimer's Disease and other Cognitive Disorders Unit, Service of Neurology, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, and the Neurologic Tissue Brain Bank, Biobanc-Hospital Clínic-IDIBAPS, Barcelona (L.M.P.) - all in Spain; the Department of Genetics, Harvard Medical School, Boston (K.C.); the Department of Neurology, University Hospital Basel, University of Basel, Basel, Switzerland (S.N.); and the Department of Neurology (V.N., S.V., M.B., A.N.) and the Molecular Genetics Laboratory, Department of Psychiatry (M.P.), National Institute of Mental Health and Neurosciences, Bengaluru, India.

Article Synopsis
  • Researchers identified a pathogenic GAA repeat expansion in the first intron of the gene that encodes fibroblast growth factor 14, linked to late-onset cerebellar ataxia (LOCA) in six French Canadian patients.
  • The expansion was significantly associated with LOCA in both French Canadian and German populations, indicating a strong genetic link with high odds ratios.
  • Analysis revealed that the expansion occurred in various percentages of patients from different backgrounds, and affected individuals showed reduced RNA and protein expression related to the condition.
View Article and Find Full Text PDF

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

N Engl J Med

December 2022

From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and the University of Melbourne, Melbourne, VIC (M.J.D.), and Prince of Wales Hospital and the University of New South Wales, Sydney (M. Hertzberg) - all in Australia; Humanitas University and Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital (C.C.-S.), and Università degli Studi di Milano and Fondazione IRCCS Istituto Nazionale dei Tumori (P.C.) - all in Milan; Université de Lille, Centre Hospitalier Universitaire (CHU) Lille, Unité Labellisée de Recherche 7365, Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille (F.M.), Centre Hospitalier Lyon Sud, Lyon (E.B.), and CHU de Montpellier, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5535, Montpellier (G.C.) - all in France; Vall d'Hebron University Hospital (G.I.) and Institut Català d'Oncologia Hospitalet, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona (A.S.) - both in Barcelona; the Allegheny Health Network Cancer Institute, Pittsburgh (C.K.); Uniwersytet Medyczny we Wrocławiu, Wroclaw, Poland (T.W.); Universitair Ziekenhuis Gent, Ghent, Belgium (F.O.); the First Faculty of Medicine, Charles University Hospital, Prague, Czech Republic (M.T.); National Taiwan University Hospital, Taipei (S.-J.W.); F. Hoffmann-La Roche, Basel, Switzerland (D.P.-C., L.L.); Roche Products, Welwyn Garden City, United Kingdom (J.R., M.D., E.C., K.H.); and Rigshospitalet, Copenhagen (M. Hutchings).

Article Synopsis
  • Glofitamab, a bispecific antibody, shows promise for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL), with 39% of patients achieving a complete response after treatment.
  • In a phase 2 trial involving patients who had undergone at least two previous therapies, the medication was administered following obinutuzumab pretreatment to reduce side effects.
  • Although the treatment was effective, 78% of complete responses were ongoing at 12 months, but 62% of patients experienced significant adverse events, primarily cytokine release syndrome.
View Article and Find Full Text PDF

Clonal haematopoiesis involves the expansion of certain blood cell lineages and has been associated with ageing and adverse health outcomes. Here we use exome sequence data on 628,388 individuals to identify 40,208 carriers of clonal haematopoiesis of indeterminate potential (CHIP). Using genome-wide and exome-wide association analyses, we identify 24 loci (21 of which are novel) where germline genetic variation influences predisposition to CHIP, including missense variants in the lymphocytic antigen coding gene LY75, which are associated with reduced incidence of CHIP.

View Article and Find Full Text PDF

Throughout the COVID-19 pandemic, a portion of those affected have evolved toward acute hypoxic respiratory failure. Initially, this was hypothesized to result from acute lung injury leading to acute respiratory distress syndrome (ARDS). In previous research, a novel quantitative CT post-processing technique was described to quantify the volume of blood contained within pulmonary blood vessels of a given size.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the genetic links to the structure of the brain's folds by analyzing data from 40,169 individuals using MRI scans from the UK Biobank.
  • Researchers found 388 associations between regional brain folding and 77 genetic loci, with genes in these areas tied to brain development and functioning.
  • The findings also include an interactive 3D visualization to help explore these associations, emphasizing their potential for studying brain health and neuropsychiatric conditions in the future.
View Article and Find Full Text PDF

Objectives: To evaluate how sociodemographic factors influence educational modality preferences in people with cardiometabolic disease.

Methods: This was a cross-sectional study performed in people with diabetes and cardiovascular disease, who completed a questionnaire to denote their previous experience and ranked preferences for different educational modalities.

Results: The questionnaire was completed by 3751 people, of whom 59% were men, median (interquartile range) age was 68 (59-76) years, and 78% were White European.

View Article and Find Full Text PDF
Article Synopsis
  • - Large biobanks that combine electronic health records with genetic data enable detailed studies on genetics related to complex diseases, focusing on age of onset, progression, and lifespan.
  • - The proposed frailty model for analyzing these genetic associations considers population structure and relatedness, employing advanced optimization techniques to handle high computational demands.
  • - The effectiveness of this method was validated using simulations and real data from around 400,000 UK Biobank participants and 180,000 FinnGen participants, yielding insights into 871 traits related to time-to-event phenotypes.
View Article and Find Full Text PDF

Genome-wide association studies (GWASs) have identified hundreds of loci associated with Crohn's disease (CD). However, as with all complex diseases, robust identification of the genes dysregulated by noncoding variants typically driving GWAS discoveries has been challenging. Here, to complement GWASs and better define actionable biological targets, we analyzed sequence data from more than 30,000 patients with CD and 80,000 population controls.

View Article and Find Full Text PDF

Numerous studies demonstrated the lack of transferability of polygenic score (PGS) models across populations and the problem arising from unequal presentation of ancestries across genetic studies. However, even within European ancestry there are ethnic groups that are rarely presented in genetic studies. For instance, Russians, being one of the largest, diverse, and yet understudied group in Europe.

View Article and Find Full Text PDF